Lupus Advocacy Requests Granted in 2018 Budget Bill

New York, NY, March 23, 2018 --(PR.com)-- The Omnibus Appropriations bill for Fiscal Year 2018
approved by the House of Representatives 256 to 167 today includes key provisions the Lupus Research
Alliance and lupus advocates have worked for all year. Lupus advocates, participating just two days
before the vote in our annual Capitol Hill Day, had requested program funding for 2019 and had asked
legislators to also finish the spending bill for Fiscal Year 2018. The legislation is well on its way to
becoming law; it now moves to the Senate for a vote and the President has signaled that he will sign it.

As requested by lupus advocates, the omnibus spending bill provides an additional $3 billion for
biomedical research funded by the National Institutes of Health as well as $5 million to continue the
Lupus Research Program at the Department of Defense (DoD) first established in 2017. The organization
is particularly proud to see the tremendous success of this program which our advocates have worked on
securing for over 10 years.

Appropriations Dedicated for Lupus Research

DoD data show that women - the primary population affected by lupus - now make up a much greater
share of our armed forces and veterans than ever before. Lupus also disproportionately targets women of
color; a recent report found that the active-duty female force is racially diverse.

Bill Supports Request for NIH Funding Increase

The bill provides a total of $37 billion for NIH, an increase of $3 billion above the fiscal year 2017
enacted level.

“More research funding is urgently needed for people with lupus and all chronic diseases,” noted Kenneth
M. Farber, CEO and President, Lupus Research Alliance. “Only one drug has ever been approved
specifically for lupus, and the drugs borrowed from other diseases like cancer can have serious side
effects. Our organization allows investigators to pursue the most innovative ideas that can make a
tremendous difference in the field. But they must also be able to go further with the support that comes
from the NIH to turn their discoveries into the improvements in the diagnosis, treatment, and prevention
people with lupus need and deserve.”

Strong Leadership from the Congressional Lupus Caucus

Lupus research continues as a top priority of the Congressional Lupus Caucus led by Co-chairs
Representatives Tom Rooney (R-FL), William Keating (D-MA), Ileana Ros-Lehtinen (R-FL) and Eddie
Bernice Johnson (D-TX). The Caucus has responded extremely positively to Lupus Research Alliance
advocates who met and contacted their legislators. The Lupus Research Alliance also thanks House
Appropriations Chairman Rodney Frelinghuysen (R-NJ) and Defense Subcommittee Chair Kay Granger
(R-TX) for their commitment to the lupus community.

About Lupus
Lupus is a chronic, complex autoimmune disease that affects millions worldwide. More than 90% of
people with lupus are women; the majority are diagnosed between the ages of 15 to 44. Women of color

Page 1/3
PR.com Press Release Distribution Terms of Use
are especially at risk. In lupus, the immune system, which is designed to protect against infection, creates
antibodies that attack the body's own tissues and organs -- the kidneys, brain, heart, lungs, blood, skin,
and joints.

About the Lupus Research Alliance

The Lupus Research Alliance aims to transform treatment while advancing toward a cure by financing the
most innovative lupus research in the world. The organization's stringent peer review grant process
fosters diverse scientific talent who are driving discovery toward better diagnostics, improved treatments
and ultimately a cure for lupus. Because the Lupus Research Alliance's Board of Directors fund all
administrative and fundraising costs, 100% of all donations goes to support lupus research programs.

Page 2/3
PR.com Press Release Distribution Terms of Use
Contact Information:
Lupus Research Alliance
Margy Meislin
646-884-6025
Contact via Email
www.LupusResearch.org

Online Version of Press Release:

You can read the online version of this press release at: https://www.pr.com/press-release/748585

Page 3/3
PR.com Press Release Distribution Terms of Use